The FDA has approved daratumumab plus hyaluronidase combined with bortezomib, cyclophosphamide, and dexamethasone (VCd) for patients with newly-diagnosed AL amyloidosis.
Study findings presented at ASH 2020 propose a recommended dose of CAEL-101 for use in combination with CyBorD in phase 3 clinical trials of patients with AL amyloidosis.
True or False: According to Palladini et al, daratumumab plus cyclophosphamide, bortezomib, and dexamethasone (CyBorD) was well tolerated and yielded robust hematologic and organ responses in…
True or False: sBCMA is a solubilized form of B-cell maturation antigen that is elevated in B-cell cancers, including MM, CLL, and AL amyloidosis.
In a study of patients with light chain (AL) amyloidosis, daratumumab plus CyBorD was shown to produce robust responses and was well-tolerated.
The FDA has granted accelerated approval to belantamab mafodotin-blmf for the treatment of adults with relapsed or refractory MM previously given at least 4 therapies.
At the virtual Great Debates & Updates in Hematologic Malignancies, Jonathan Kaufman, MD, discussed the standard front-line approach for treating patients with MM ineligible for transplantation.
Researchers identified genomic predictors of progression that could help distinguish patients with smoldering MM at high risk for progression to MM.
Once weekly selinexor, bortezomib, and dexamethasone significantly improved PFS and ORR compared to standard twice weekly bortezomib and dexamethasone for MM.